Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Part of paid clinical trials in Duarte, California.

Sponsor
PhotonPharma, Inc.
Study ID
NCT06366490
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Ovarian Cancer
  • Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Innocell Autologous Cellular Immunotherapy — BIOLOGICAL
    Innocell Autologous Cellular Immunotherapy cells will be administered with CpG 1018 adjuvant ID every 2 weeks x 3 doses

Study Details

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer

Key Dates

Start date
Feb 12, 2026
Status verified
Mar 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Innocell an Autologous Cellular Immunotherapy
    Innocell autologous immunotherapy will be administered with CpG 1018 adjuvant

Primary Outcome Measure

Success rate of autologous manufacturing [ Time Frame: 2 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Mihae Song, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
City of Hope· Duarte, CA

Related Studies